- Home
- CLDI vs CVKD Comparison
CLDI vs CVKD Comparison
Compare CLDI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- CVKD
- Stock Information
- Founded
- CLDI 2014
- CVKD 2022
- Country
- CLDI United States
- CVKD United States
- Employees
- CLDI N/A
- CVKD N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- CLDI Health Care
- CVKD Health Care
- Exchange
- CLDI Nasdaq
- CVKD Nasdaq
- Market Cap
- CLDI 35.2M
- CVKD 34.2M
- IPO Year
- CLDI N/A
- CVKD 2023
- Fundamental
- Price
- CLDI $1.05
- CVKD $19.89
- Analyst Decision
- CLDI Strong Buy
- CVKD Strong Buy
- Analyst Count
- CLDI 3
- CVKD 1
- Target Price
- CLDI $16.67
- CVKD $32.00
- AVG Volume (30 Days)
- CLDI 2.7M
- CVKD 37.3K
- Earning Date
- CLDI 03-14-2025
- CVKD 03-10-2025
- Dividend Yield
- CLDI N/A
- CVKD N/A
- EPS Growth
- CLDI N/A
- CVKD N/A
- EPS
- CLDI N/A
- CVKD N/A
- Revenue
- CLDI N/A
- CVKD N/A
- Revenue This Year
- CLDI N/A
- CVKD N/A
- Revenue Next Year
- CLDI N/A
- CVKD N/A
- P/E Ratio
- CLDI N/A
- CVKD N/A
- Revenue Growth
- CLDI N/A
- CVKD N/A
- 52 Week Low
- CLDI $0.58
- CVKD $5.40
- 52 Week High
- CLDI $16.80
- CVKD $20.79
- Technical
- Relative Strength Index (RSI)
- CLDI 45.04
- CVKD 59.16
- Support Level
- CLDI $1.16
- CVKD $18.87
- Resistance Level
- CLDI $1.30
- CVKD $20.26
- Average True Range (ATR)
- CLDI 0.24
- CVKD 1.19
- MACD
- CLDI 0.01
- CVKD -0.08
- Stochastic Oscillator
- CLDI 40.10
- CVKD 82.52
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.